Epigenetic signatures of familial cancer are characteristic of tumor type and family category.

Tumor suppressor genes (TSG) may be inactivated by methylation of critical CpG sites in their promoter regions, providing targets for early detection and prevention. Although sporadic cancers, especially colorectal carcinoma (CRC), have been characterized for epigenetic changes extensively, such information in familial/hereditary cancer is limited. We studied 108 CRCs and 63 endometrial carcinomas (EC) occurring as part of hereditary nonpolyposis CRC, as separate familial site-specific entities or sporadically, for promoter methylation of 24 TSGs. Eleven genes in CRC and 6 in EC were methylated in at least 15% of tumors and together accounted for 89% and 82% of promoter methylation events in CRC and EC, respectively. Some genes (e.g., CDH13, APC, GSTP1, and TIMP3) showed frequent methylation in both cancers, whereas promoter methylation of ESR1, CHFR, and RARB was typical of CRC and that of RASSF1(A) characterized EC. Among CRCs, sets of genes with methylation characteristic of familial versus sporadic tumors appeared. A TSG methylator phenotype (methylation of at least 5 of 24 genes) occurred in 37% of CRC and 18% of EC (P = 0.013), and the presence versus absence of MLH1 methylation divided the tumors into high versus low methylation groups. In conclusion, inactivation of TSGs by promoter methylation followed patterns characteristic of tumor type (CRC versus EC) and family category and was strongly influenced by MLH1 promoter methylation status in all categories. Paired normal tissues or blood displayed negligible methylation arguing against a constitutional methylation abnormality in familial cases.

[1]  H. Morreau,et al.  Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair–Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways , 2007, Clinical Cancer Research.

[2]  P. Peltomäki,et al.  Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma , 2007, International journal of cancer.

[3]  C. Lindgren,et al.  Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach , 2007, Oncogene.

[4]  Arndt Hartmann,et al.  Distinction of Hereditary Nonpolyposis Colorectal Cancer and Sporadic Microsatellite-Unstable Colorectal Cancer through Quantification of MLH1 Methylation by Real-time PCR , 2007, Clinical Cancer Research.

[5]  C. Caldas,et al.  Cancer genetics of epigenetic genes. , 2007, Human molecular genetics.

[6]  David I. K. Martin,et al.  Inheritance of a cancer-associated MLH1 germ-line epimutation. , 2007, The New England journal of medicine.

[7]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[8]  P. Peltomäki,et al.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study , 2007, Gut.

[9]  M. Urioste,et al.  MLH1 germline epimutations in selected patients with early‐onset non‐polyposis colorectal cancer , 2007, Clinical genetics.

[10]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[11]  S. Leung,et al.  Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.

[12]  W. Chapman,et al.  CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer , 2006, Genes, chromosomes & cancer.

[13]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[14]  J. Schouten,et al.  Epigenetic events of disease progression in head and neck squamous cell carcinoma. , 2006, Archives of otolaryngology--head & neck surgery.

[15]  B. Leggett,et al.  DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients , 2006, International journal of cancer.

[16]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[17]  J. Schouten,et al.  Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences , 2005, Nucleic acids research.

[18]  P. Peltomäki,et al.  Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Rossi,et al.  Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  P. Catalano,et al.  Phenotype of Microsatellite-Stable Colorectal Carcinomas With CpG Island Methylation , 2005, The American journal of surgical pathology.

[21]  J. Hopper,et al.  Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  S. Knuutila,et al.  Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations , 2005, Oncogene.

[23]  J. Issa,et al.  CpG island methylation in gastroenterologic neoplasia: a maturing field. , 2004, Gastroenterology.

[24]  A. Lindblom,et al.  Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Amos,et al.  Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. , 2003, Cancer research.

[26]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[27]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[28]  P. Peltomäki.  Role of DNA mismatch repair defects in the pathogenesis of human cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[30]  F. Bazzoli,et al.  Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. , 2003, Cancer research.

[31]  M. Verma,et al.  Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.

[32]  M. Loda,et al.  A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. , 2002, Cancer research.

[33]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[34]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[35]  P. Peltomäki,et al.  Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. , 2001, Cancer research.

[36]  J. Herman,et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. , 2000, Cancer research.

[37]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[38]  J. Herman,et al.  hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. , 1999, The American journal of pathology.

[39]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Deng,et al.  Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. , 1999, Cancer research.

[41]  Manel Esteller,et al.  MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.

[42]  L. Kasturi,et al.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Devries,et al.  Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. , 1994, The American journal of pathology.

[45]  J. Mecklin,et al.  Screening for colorectal carcinoma in cancer family syndrome kindreds. , 1987, Scandinavian journal of gastroenterology.

[46]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.

[47]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[48]  David I. K. Martin,et al.  Germline epimutation of MLH1 in individuals with multiple cancers , 2004, Nature Genetics.

[49]  A. de la Chapelle,et al.  Mutation sharing, predominant involvement of the MLH1 gene and description of four novel mutations in hereditary nonpolyposis colorectal cancer , 1998, Human mutation.

[50]  X. Estivill,et al.  Two novel mutations in exon 11 of the PAH gene (V1163 del TG and P362T) associated with classic phenylketonuria and mild phenylketonuria , 1998, Human mutation.